SUBSCRIBE: RSS Feed for Spinal Cord Injury Zone Email Updates Follow Spinal Cord Injury Zone on Twitter Spinal Cord Injury Zone on Facebook

Articles Tagged: Clinical Trial

Nanoparticles limit damage in spinal cord injury

Published: September 5, 2017 | Category: News

Injection after an injury reduces inflammation and scarring

After a spinal cord injury, a significant amount of secondary nerve damage is caused by inflammation and internal scarring that inhibits the ability of the nervous system to repair itself.

A biodegradable nanoparticle injected after a spinal cord trauma prevented the inflammation and internal scarring that inhibits the repair process, reports a new Northwestern Medicine study. Continue Reading »

It’s Not a Rat’s Race for Human Stem Cells Grafted to Repair Spinal Cord Injuries

Published: August 28, 2017 | Category: News

Lengthy study finds that implanted neural stem cells grow slow and steady, and success needs to be measured accordingly

More than one-and-a-half years after implantation, researchers at University of California San Diego School of Medicine and the San Diego Veterans Administration Medical Center report that human neural stem cells (NSCs) grafted into spinal cord injuries in laboratory rats displayed continued growth and maturity, with functional recovery beginning one year after grafting. Continue Reading »

Q Therapeutics Approved to Start Trial of Cell Therapy Aiming to Restore Myelin

Published: July 26, 2017 | Category: News

A cell therapy intended to boost myelin regeneration — Q-Cells by Q Therapeutics — has received a green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that like multiple sclerosis is characterized by myelin damage.

FDA approval of the company’s Investigational New Drug (IND) application allows researchers to start a Phase 1/2 clinical trial in which nine patients will receive increasing doses of the treatment. Continue Reading »

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Published: July 10, 2017 | Category: News | Spinal Cord Injury:

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials

FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in motor complete cervical spinal cord injury (SCI). The amendment expands the eligibility criteria to include patients with a C-4 spinal cord injury and extends the dosing window from 14 to 30 days to 21 to 42 days post-injury. Continue Reading »

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1

Published: June 13, 2017 | Category: News

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side

FREMONT, Calif., June 13, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months. Continue Reading »

Man with quadriplegia employs injury bridging technologies to move again—just by thinking

Published: March 28, 2017 | Category: News | Spinal Cord Injury: ,

First recipient of implanted brain-recording and muscle-stimulating systems reanimates limb that had been stilled for eight years. Continue Reading »

Using a Mini-Scaffold to Help Treat Spinal Cord Injury

Published: February 28, 2017 | Category: News

Patients suffering from complete spinal cord injuries have little to no treatment options that provide meaningful improvement in patient outcomes.

Cambridge, Mass.-based InVivo Therapeutics is trying to change that. Co-founded in 2005 by MIT professor Robert Langer, and surgeon-scientists Joseph Vacanti, M.D., the company has developed a small, bioresorbable and biocompatible device called the Neuro-Spinal Scaffold, to help patients with complete thoracic spinal cord injuries regain some function. Continue Reading »

Brain-computer interface advance allows fast, accurate typing by people with paralysis

Published: February 21, 2017 | Category: News

In a Stanford-led research report, three participants with movement impairment controlled an onscreen cursor simply by imagining their own hand movements.

A clinical research publication led by Stanford University investigators has demonstrated that a brain-to-computer hookup can enable people with paralysis to type via direct brain control at the highest speeds and accuracy levels reported to date. Continue Reading »

UCLA researcher tackles paralysis with electrical stimulation devices

Published: February 10, 2017 | Category: News

A UCLA professor is helping paralyzed individuals regain use of their limbs through electric stimulation of the spinal cord.

In 2015, Reggie Edgerton, the director of the Neuromuscular Research Laboratory at UCLA, developed a robotic exoskeleton that helped a paralyzed man walk. Though the man is still paralyzed and cannot control the exoskeleton’s movement, Edgerton’s lab plans to do more research to make that happen. Continue Reading »

Generating improvement in spinal cord injuries

Published: January 24, 2017 | Category: News

Early clinical trial results announced offer new hope in regenerative medicine

A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1. Continue Reading »